![]() |
市場調查報告書
商品編碼
1383449
2030 年全球微陣列市場預測:按產品、類型、應用、最終用戶和地區進行的全球分析Microarray Market Forecasts to 2030 - Global Analysis By Product (Consumables, Instruments and Software & Services), Type, Application, End User and By Geography |
根據 Stratistics MRC 的數據,2023 年全球微陣列市場規模將達到 47 億美元,預計到 2030 年將達到 90.4 億美元,預測期內年複合成長率為 9.8%。
在基因組學和分子生物學中,微陣列是一種有效的技術,可以同時高通量研究許多基因、蛋白質和其他物質。該市場由多種類型的微陣列組成,包括 DNA、蛋白質和組織微陣列,在研究、診斷和藥物開發方面提供廣泛的應用。自訂微陣列由多個組織和研究人員創建,以滿足他們獨特的研究需求。
根據英國皇家化學學會 2019 年發表的一項研究,連接到智慧型手機的攜帶式螢光微陣列成像系統正在用於檢測乳癌基因表現。
由於微陣列被用於各種應用,微陣列市場正在擴大。隨著越來越多的科學家和組織在臨床診斷、蛋白質組學、基因組學和其他領域使用微陣列,對微陣列產品和服務的需求不斷增加。近年來,微陣列已被應用於藥物開發、蛋白質體學、臨床診斷、基因組學和環境監測等更多領域。這種多樣性使得市場對特定產業的變化更具彈性,並使其不斷發展。藥物開發在很大程度上依賴微陣列,因為它們有助於標靶識別、毒性評估和生物標記發現。
次世代定序技術可以獲得完整的分子和基因組資料。因此,微陣列在各種應用中的市場佔有率正在下降。次世代定序儀因其廣泛的資訊和執行高通量測序的能力而經常被研究人員和醫生使用。在考慮技術時,人們很容易認為次世代定序儀比微陣列更強大、更複雜。這種思維方式不利於在研究和其他情況下使用微陣列而支援次世代定序儀,並可能阻礙微陣列業務的擴展。
個別患者的分子分析是個人化醫療製化藥物介入的基礎。微陣列對於創建每個患者特有的遺傳和分子資料至關重要。患者和醫療保健專業人員對個體化醫療潛在好處的認知不斷提高,導致對這些技術的需求激增。在個體化醫療領域,研究人員、醫療保健專業人員和生技公司之間的跨學科合作正變得越來越廣泛。
缺乏合格人員可能會阻礙微陣列技術的採用。如果研究機構和臨床實驗室缺乏具備正確操作技術所需技能的員工,他們可能不願意投資微陣列平台。分析微陣列資料很困難,需要生物資訊學知識。缺乏合格的專家可能會導致資料處理效率低下、研究結果延遲或誤解,並減少科學產出。
微陣列透過研究宿主對病毒的反應、改變患者的基因表現以及創建診斷測試,為 COVID-19 研究做出了貢獻。因此,對基於病毒特異性微陣列的測試的需求增加。因此,疫情導致某些地區的研究資金籌措目標發生變化,重點是疫苗開發和感染疾病研究。此外,一旦大流行的嚴重階段過去,隨著更多資金投入蛋白質體學和基因組學等生命科學研究,微陣列市場可能會成長。
在蛋白質體學研究中,蛋白質微陣列是研究蛋白質的性質、關係和作用的有效且適應性強的工具,因此蛋白質微陣列領域預計將經歷良好的成長。與檢查基因表現的 DNA 微陣列相比,蛋白質微陣列能夠對蛋白質和其他分子之間的結合相互作用進行高通量分析。蛋白質微陣列技術的進步正在產生日益複雜的系統,其靈敏度、特異性和通量也不斷提高。
與遺傳疾病、癌症、感染疾病和染色體異常相關的單核苷酸多態性(SNP)都是使用這些微陣列發現的,使得疾病診斷領域有望在預測期內出現最高的年複合成長率年成長率。這些微陣列使用組織切片和培養細胞來研究各種疾病中的蛋白質-蛋白質相互作用、基因表現模式和蛋白質定位。此外,這些診斷微陣列可以在個人化醫療時代根據患者的遺傳和分子特徵量身定做治療計劃,從而促進市場成長。
預計亞太地區將在預測期內佔據最大的市場佔有率,因為對尖端醫療保健解決方案的需求不斷成長以及基因組學和個人化醫療研發的加強正在推動市場擴張。亞太地區是積極從事微陣列研究和開發的學術機構、研究機構和生物技術公司的所在地。這包括為特定應用創建微陣列以及識別各種疾病的生物標記。
北美是微陣列技術最大、最發達的市場之一,因此預計在預測期內年複合成長率最高。尤其美國,是微陣列生產和研究的重要中心。北美微陣列市場由許多提供微陣列平台、試劑和服務的跨國和本地公司主導。安捷倫科技、Illumina、Thermo Fisher Scientific、PerkinElmer 等是該領域的主要企業,正在推動該地區的市場成長。
According to Stratistics MRC, the Global Microarray Market is accounted for $4.70 billion in 2023 and is expected to reach $9.04 billion by 2030 growing at a CAGR of 9.8% during the forecast period. In genomics and molecular biology, microarrays are an effective technology that allow for the high-throughput, simultaneous investigation of many genes, proteins, or other substances. The market offers a broad variety of applications in research, diagnostics, and drug development and comprises many types of microarrays, including DNA, protein, and tissue microarrays. Custom microarrays are created by several organizations and researchers to meet their unique research requirements.
According to a research study published by the Royal Society of Chemistry in 2019, a portable fluorescence microarray imaging system that connects to a smartphone has been used for the detection of breast cancer gene expression.
The market for microarrays has grown as a result of the growing use of microarrays in various applications. The need for microarray goods and services has increased as more scientists and organizations use them for clinical diagnostics, proteomics, genomics, and other areas. These days, microarrays are employed in many more fields, such as drug development, proteomics, clinical diagnostics, genomics, and environmental monitoring due to this diversity, the market is now more resilient to changes in certain industries and has been able to develop continuously. Drug development relies heavily on microarrays because they make target identification, toxicity assessment, and biomarker discovery easier.
Next-generation sequencing technologies can give complete molecular and genomic data; they have become more and more popular. They have so reduced microarrays' market share across a range of applications. Because of Next-generation sequencing breadth of information and high-throughput sequencing capabilities, researchers and physicians frequently use it. When considering technologies, it is frequently thought to be more potent and sophisticated than microarrays. This idea may discourage the use of microarrays in favour of next-generation sequencing in research and other settings, which might stunt the expansion of the microarray business.
Molecular profiling of individual patients is the foundation of personalized medicine, which customizes medicinal interventions. In order to produce genetic and molecular data particular to each patient, microarrays are essential. The growing awareness among patients and healthcare professionals of the potential advantages of customized medicine has led to a surge in demand for these technologies. In the realm of customized medicine, interdisciplinary collaboration between researchers, healthcare practitioners, and biotechnology businesses is becoming more widespread.
Microarray technology adoption may be hindered by the lack of qualified workers. If research organizations and clinical labs lack the staff with the necessary skills to properly run the technology, they can be reluctant to invest in microarray platforms. The analysis of microarray data might be challenging and call for bioinformatics knowledge. A shortage of qualified experts might lead to ineffective data processing, which would postpone research results, misunderstand them, and decrease scientific output thus hampering the market growth.
Through the investigation of host responses to the virus, patient gene expression alterations, and the creation of diagnostic tests, microarrays contributed to COVID-19 research. As a result, there was a rise in demand for virus-specific microarray-based tests. Thus, the pandemic caused changes in certain regions' objectives for financing research, with an emphasis on developing vaccines and researching infectious diseases. Furthermore, the market for microarrays may grow if more money is invested in life sciences research, like as proteomics and genomics, once the pandemic's acute phase has passed.
The protein microarrays segment is estimated to have a lucrative growth, as these proteomics research, protein microarrays are an effective and adaptable tool for examining the characteristics, relationships, and roles of proteins. Protein microarrays enable high-throughput analysis of the binding interactions of proteins and other molecules, much to DNA microarrays, which are used to examine gene expression. The advancement of protein microarray technology has produced increasingly sophisticated systems with improved sensitivity, specificity, and throughput.
The diseases diagnostics segment is anticipated to witness the highest CAGR growth during the forecast period, because the single nucleotide polymorphisms (SNPs) linked to genetic disorders, cancer, and infectious illnesses, as well as chromosomal abnormalities, are all found using these microarrays. These microarrays investigate protein-protein interactions, gene expression patterns, and protein localization in a variety of disorders using tissue slices or cultured cells. Moreover these diagnostic microarrays allow for customized treatment plans based on a patient's genetic or molecular profile in the age of personalized medicine thereby boosting the market growth.
Asia Pacific is projected to hold the largest market share during the forecast period owing to the rising demand for cutting-edge healthcare solutions as well as enhanced genomics and personalized medicine research and development efforts are responsible for this expansion. The Asia Pacific area is home to several academic institutions, research labs, and biotechnology corporations that are actively involved in microarray research and development. This involves the creation of personalized microarrays for particular uses and the identification of biomarkers for a range of illnesses.
North America is projected to have the highest CAGR over the forecast period; owing to one of the biggest and most developed markets for microarray technology. Particularly, the US is a significant centre for microarray creation and research. The North American microarray market is occupied by a number of multinational and local businesses that offer microarray platforms, reagents, and services. Agilent Technologies, Illumina, Thermo Fisher Scientific, PerkinElmer, and many more are some of the major companies in this sector are driving the market growth in this region.
Some of the key players profiled in the Microarray Market include: Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., PerkinElmer, Inc., Bio-Rad Laboratories, GE Healthcare, Molecular Devices, LLC, Affymetrix, Merck & Co., Inc., Arrayit Corporation, Microarrays; Inc., NextGen Sciences, bioMerieux SA, RayBiotech Life, Inc, PathogenDx, Diasorin Group, Schott Minifab, Full Moon Biosystems.Inc and CapitalBio Technology Co, Ltd
In October 2023, Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Meridian™ EX System an electron-beam-based failure analysis solution designed to enable precise fault localization on advanced semiconductor logic technologies.
In October 2023, Thermo Fisher Scientific announced a companion diagnostic (CDx) partnership with Boehringer Ingelheim. Through this collaboration, the companies will work to develop CDx tests to help identify patients with non-small cell lung cancer (NSCLC) with specific genomic mutations.
In September 2023, Agilent Technologies Inc recently signed a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) outlining their collaboration to accelerate translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years.